ReviewPeerJ2026
Advances in novel biomaterials for cardiovascular tissue engineering and regenerative medicine.
Review in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Biomaterial-Assisted Stem Cell Therapy and Exosome Delivery in Myocardial Infarction: A Narrative Review.Biomimetics (Basel, Switzerland) · 2026Review
- Evolutions in Cardiovascular Implants-A Review of Past, Present, and Future.Micromachines · 2026Review
- Advancements and Challenges in Tissue-Engineered Heart Valves: Integrating Biomechanics, Biomaterials, and Biomimetic Design for Functional Maturity.Biomimetics (Basel, Switzerland) · 2026Review
- A "Vascular Band-Aid" strategy for proactive inhibition of post-anastomotic vascular complications.Regenerative biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases remain a leading cause of mortality worldwide, with conventional treatments such as pharmacotherapy and surgery presenting significant limitations. In recent years, novel biomaterials have emerged as a promising avenue in cardiovascular tissue engineering and regenerative medicine, offering innovative solutions for disease treatment. This review highlights the current applications and latest advancements of these biomaterials in cardiovascular tissue engineering, emphasizing their potential to enhance myocardial regeneration, vascular repair, and heart valve replacement. Key developments in biocompatible scaffolds, bioactive hydrogels, and smart biomaterials are discussed, along with their roles in promoting cell adhesion, proliferation, and differentiation. Additionally, the review addresses the challenges associated with clinical translation, including biocompatibility, mechanical stability, and long-term efficacy. By exploring future directions, this article aims to provide insights into the transformative potential of biomaterials in revolutionizing cardiovascular therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.